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LGB is employed by the Desmond Tutu HIV Centre, UCT and the Desmond Tutu HIV Foundation. She has received honoraria for technical inputs from Jansen and Merck in the last 5 years and her organisation has benefited from grants from Gilead, Merck and ViiV. SD, SL, and LGB served as guest editors on PLOS Medicine's prospects for customized interventions to achieve the UNAIDS targets in HIV care. Batya Elul and colleagues performed a cluster-randomized trial in Mozambique and found that a similar intervention improved linkage to care and retention at 1 year [12] .
Harsh political realities can also be a barrier; this is perhaps best illustrated in the intensifying crisis that is the HIV epidemic in the Russian Federation, discussed in a Perspective by Chris Beyrer and coauthors [13] . Here, as occurred in other countries earlier in the global epidemic with disastrous results, HIV infections are multiplying in key populations that lack societal attention and are denied proven healthcare interventions. In the Russian Federation and other regions where anachronistic policies and laws in relation to injection drug use and MSM fuel the spread of HIV, immediate action is needed to reverse the growth of local epidemics.
Biomedical methods to prevent HIV acquisition have undergone a resurgence in research and development in the last decade with the demonstration that ART given either as pre-exposure prophylaxis (for an uninfected individual) or as treatment (for an infected individual) can prevent transmission. Combination prevention packages are now being tailored for different populations; these approaches often take a more holistic approach and include harm reduction for people who inject drugs and social protection for young unemployed women.
Despite these advances, it is generally assumed that an effective vaccine will be needed to ultimately end the spread of HIV. In another Perspective, Lynn Morris and Nonhlanhla Mkhize discuss the prospects for broadly neutralizing antibodies (BNAbs) to contribute to HIV prevention efforts by eliciting passive immunity [14] , and Ken Mayer and colleagues report a phase 1 trial of VRC01, a BNAb that is proceeding to large-scale evaluation [15] . It is hoped that such BNAb studies might identify novel therapies for prevention and provide important insights for the development of more scalable vaccines. Whether by generating active or passive immunity, supplementing the available prevention strategies with an effective vaccine remains of critical importance in circumventing the issues of adherence that affect many current approaches, with potentially transformative benefits in specific settings and populations.
For those who can access ART, residual concerns persist. For example, for reasons that remain largely undefined, HIV-infected adults on otherwise effective therapy have an excess risk of developing a number of non-AIDS complications. These complications include cardiovascular disease and kidney disease, and in a study based on the D:A:D collaboration, Mark Boyd and colleagues describe a multiplicative increase in events in people at high risk of cardiovascular and renal disease [16] , which has implications for long-term management.
Due in part to problems in retaining people in care and the apparent inability of ART to fully restore health [16] , there is now a major global scientific effort to find a cure for HIV disease. Although ART prevents HIV from replicating, it does not eliminate a stable reservoir of infected cells that persists indefinitely. Approaches to reducing this reservoir include starting ART very early (before the reservoir is established) or reconstructing a new HIV-free immune system through hematopoietic stem cell transplantation. Timothy Henrich and colleagues report an extraordinary case of what happened when ART was initiated on essentially the first day an infection might be diagnosed, estimated to be roughly 10 days post-infection [17] . The reservoir of replication-competent virus in this individual was several orders of magnitude lower than that observed when ART was started during chronic infection, but unfortunately the person was not cured as, even during this brief period of time, approximately 200 stably infected cells were established. A similar state of prolonged time to rebound, once ART was stopped, was achieved in an HIV-infected individual who received an allogeneic stem cell transplantation, as demonstrated by Andrew Badley and colleagues [18] . For the initial 10 months off ART, virus was undetectable but eventually rebounded. Careful sequencing of the rebound virus did not match virus sequenced in blood prior to transplantation, highlighting the great challenge in understanding the main source of viral rebound off ART. Furthermore, it is now clear that simply reducing virus, even by several logs, will not lead to durable remission without ART.
The aspirational slogan Let's End It suggests that the goal of ending the epidemic is in our grasp and hinges only on our collective commitment to do so. However, the remarkable progress, activism, resources, ingenuity, and sheer fortitude that have brought us this far will be needed in at least equal measure to take us to the end. Only by harnessing the maximum available resources; innovating and implementing relentlessly; and applying the fruits of these processes without prejudice to all human populations, wherever they are needed, will we be able to start imagining an end to the HIV/AIDS epidemic.
